Antibody-mediated blocking of the immune checkpoint receptors CTLA-4 and PD-(L)1 has been a mainstay in the battle against cancer; however, despite durable responses across tumor indications, the majority of cancer patients fail to respond to these agents. Here, CD274 is linked to neoplasm.